Susan Evan's update. Judicial Review Date in June re Gender Plus.

[CarefulN0w]

Copied from email. More details on the crowd justice page, I won't paste the link incase it's deleted, but it looks like additional gardening would be welcomed.

Update on PROTECT TEENAGERS FROM HARMFUL AND IRREVERSIBLE MEDICAL TREATMENT

Good News Dearest Backer!

We now have a date set for the Judicial Review. This JR will examine the CQC’s decision to register GenderPlus, and the hearing has been listed for 24/25 June 2025.
In the meantime we await evidence from the CQC and GenderPlus, which has to be with our legal team by 28th February.
Once we have seen their evidence we will be preparing for the hearing.

Further details.

^On Friday my solicitors heard from the High Court that Mr Justice Foxton had given me and parent X permission to challenge the decision of the CQC to license GenderPlus Hormone Clinic. The judge was very concerned that the CQC may have licensed GenderPlus without having all the necessary information it needed to assure itself that providing cross sex hormone treatment to teenagers was a safe treatment. The judge was also concerned that by granting licensing to GenderPlus the CQC was acting irrationally.
We now know that, in the light of the Cass Review, there are hugely significant concerns about cross sex hormone treatment. The consequences are lifelong and the evidence to support this treatment is currently extremely poor.
Our case will now proceed to trial. We are so grateful for those who have supported us thus far. We need to raise funds to get this case across the line and finally protect vulnerable teenagers from experimental treatment that is not evidenced and may have profound lifelong irreversible consequences. The serious and troubling question regarding the ability of young patients to give 'informed consent' to this treatment remains.
Please donate and share with others. Thank you so much.
Sue and Parent X^
It goes without saying that if Gender Plus were to be able to find a route to prescribe cross sex hormones to teenagers, despite the evidence in the Cass review, that other clinics would inevitably follow.